IP Library Granted Patent US 7,588,333
Granted Patent B2
US 7,588,333 · App. 12/048,169 · Granted Sep 15, 2009

Improving vision in macular degeneration patients

View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 7,588,333
App. No.
12/048,169
Granted
Sep 15, 2009
Kind
B2
Abstract

An eyeglass lens and manufacturing method using a variable refractive index material, such as epoxy. In one embodiment, a method of making an eyeglass lens includes: imaging a patient's eye to determine a wavefront prescription for the patient; and curing the lens based on the wavefront prescription such that the wavefront guided lens corrects for aberrations over the lens for a plurality of gazing angles of the patient.

Claims (8)

1. A method of treating a patient's eye with retinal dysfunction which comprises providing the patient with a spectacle lens that corrects for low order aberrations and at least one high order aberration, wherein the spectacle lens is configured to warp a patient's retinal image around dysfunctional retinal tissue of the patient's eye.

2. The method of claim 1 wherein retinal dysfunction is macular degeneration and the spectacle lenses comprise a layer of a curable material that has been cured to provide a layer having a variable refractive index which corrects the at least one high order aberration.

3. The method of claim 2 wherein the curable material is an epoxy.

4. The method of claim 3 wherein the epoxy is cured by exposure to ultraviolet radiation.

5. A retinal dysfunction-correcting spectacle lens which comprises a low order aberration-correcting lens and a layer of a curable material that has been cured to provide a layer of variable refractive index which corrects at least one high order aberration and said high order aberration correction provides improved vision to a person with the retinal dysfunction, wherein the spectacle lens is configured to warp a patient's retinal image around dysfunctional retinal tissue of the patient's eye.

6. The spectacle lens of claim 5 wherein the retinal dysfunction is macular degeneration.

7. The spectacle lenses of claim 6 wherein the curable material is an epoxy.

8. The spectacle lens of claim 7 wherein the epoxy is cured by exposure to ultraviolet radiation.

Assignments (5)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Apr 6, 2018
From: ESSILOR INTERNATIONAL (COMPAGNIE GÉNÉRALE D'OPTIQUE)
To: ESSILOR INTERNATIONAL
Reel/Frame 045853/0275 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Dec 27, 2013
From: OPHTHONIX, INC.
To: ESSILOR INTERNATIONAL (COMPAGNIE GENERALE D'OPTIQUE)
Reel/Frame 031870/0488 →
RELEASE OF SECURITY INTEREST Recorded Oct 21, 2011
From: ENTERPRISE PARTNERS VI, L.P.; KPCB HOLDINGS, INC., AS NOMINEE; TREX ENTERPRISES CORPORATION
To: OPHTHONIX, INC.
Reel/Frame 027102/0258 →
SECURITY AGREEMENT Recorded Jun 7, 2011
From: OPHTHONIX, INC.
To: ENTERPRISE PARTNERS VI, L.P.; KPCB HOLDINGS, INC., AS NOMINEE, C/O KLEINER PERKINS CAUFIELD & BYERS; TREX ENTERPRISES CORPORATION
Reel/Frame 026405/0745 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded May 12, 2009
From: DREHER, ANDREAS W.
To: OPHTHONIX, INC.
Reel/Frame 022674/0377 →